The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

1995 ◽  
Vol 20 (3) ◽  
pp. 193-201 ◽  
Author(s):  
J. Verweij ◽  
H.T. Mouridsen ◽  
O.S. Nielssen ◽  
P.J. Woll ◽  
R. Somers ◽  
...  
Diagnostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 512
Author(s):  
Celine Jacobs ◽  
Lore Lapeire

Soft tissue sarcomas are a group of rare mesenchymal tumors with more than 70 subtypes described. Treatment of these subtypes in an advanced setting is mainly according to a one-size-fits-all strategy indicating a high unmet need of new and more targeted therapeutic options in order to optimize survival. The introduction of advanced molecular techniques in cancer has led to better diagnostics and identification of new therapeutic targets, leading to more personalized treatment and improved prognosis for several cancer types. In sarcoma, a likewise evolution is seen, albeit at a slower pace. This manuscript describes how in the past years advanced molecular profiling in soft tissue sarcomas was able to identify specific and often pathognomonic aberrations, deferring standard sarcoma treatment in favor of more targeted treatment from an oncologist’s point of view.


2021 ◽  
Vol 22 (14) ◽  
pp. 7518
Author(s):  
Marcella Tazzari ◽  
Laura Bergamaschi ◽  
Alessandro De Vita ◽  
Paola Collini ◽  
Marta Barisella ◽  
...  

Soft tissue sarcomas (STSs) are a family of rare malignant tumors encompassing more than 80 histologies. Current therapies for metastatic STS, a condition that affects roughly half of patients, have limited efficacy, making innovative therapeutic strategies urgently needed. From a molecular point of view, STSs can be classified as translocation-related and those with a heavily rearranged genotype. Although only the latter display an increased mutational burden, molecular profiles suggestive of an “immune hot” tumor microenvironment are observed across STS histologies, and response to immunotherapy has been reported in both translocation-related and genetic complex STSs. These data reinforce the notion that immunity in STSs is multifaceted and influenced by both genetic and epigenetic determinants. Cumulative evidence indicates that a fine characterization of STSs at different levels is required to identify biomarkers predictive of immunotherapy response and to discover targetable pathways to switch on the immune sensitivity of “immune cold” tumors. In this review, we will summarize recent findings on the interplay between genetic landscape, molecular profiling and immunity in STSs. Immunological and molecular features will be discussed for their prognostic value in selected STS histologies. Finally, the local and systemic immunomodulatory effects of the targeted drugs imatinib and sunitinib will be discussed.


1921 ◽  
Vol 25 (123) ◽  
pp. 130-165

In the following paper the writer's aim is to indicate certain possible lines of development and research which his own investigations and preliminary experiments have shown to be at least worthy of serious consideration.If we review the present state of the art we find the position to be substantially as follows :—From a thermodynamic point of view the performance of the modern aero engine has approached so nearly to the ideal obtainable from the cycle on which it operates that there is little scope for improvement.


2017 ◽  
Vol 103 (3) ◽  
pp. 213-216 ◽  
Author(s):  
Robert S. Benjamin

Dr. Gianni Bonadonna is internationally recognized as one of the foremost medical oncologists of the 20th century. He is best known for his pioneering work in the development of adjuvant chemotherapy for breast cancer, but he was also the father of sarcoma chemotherapy. The first investigator to study the new chemotherapeutic agent adriamycin in the late 1960s, he noted activity against sarcomas. This article, focusing on adjuvant chemotherapy, adriamycin, and sarcomas, memorializes his achievements and their progeny.


2022 ◽  
Vol 11 (2) ◽  
pp. 406
Author(s):  
Maria Cecilia Cercato ◽  
Sabrina Vari ◽  
Gabriella Maggi ◽  
Wioletta Faltyn ◽  
Concetta Elisa Onesti ◽  
...  

Background. Guidelines for the implementation of narrative medicine in clinical practice exist; however, in Italy, no standard methodology is currently available for the management of oncological patients. Since 2017, at the “Regina Elena” National Cancer Institute, studies using “digital narrative diaries” (DNMLAB platform) have been carried out; this article focuses on a pilot, uncontrolled, real-life study aiming to evaluate the utility of DNM integrated with the care pathway of patients with bone and limb soft tissue sarcomas. Methods. Adult patients completed the diary during treatment or follow-up by writing their narrative guided by a set of narrative prompts. The endpoints were: (a) patients’ opinions about therapeutic alliance, awareness, and coping ability; (b) healthcare professionals’ (HCPs’) opinions about communication, therapeutic alliance, and information collection. Open- and closed-ended questions (Likert score: 1–5) were used to assess the items. Results. At the interim analysis of data from seven patients and five HCPs, DNM was shown to improve: (a) the expression of patients’ point of view, the perception of effective taking charge, disease awareness, and self-empowerment (score: 4.8/5); (b) patients’ communication, relationships, and illness knowledge (score: 4.6–4.8/5). Conclusions. The preliminary results supported the need to integrate patients’ narratives with clinical data and encourage further research.


2005 ◽  
Vol 70 (5) ◽  
pp. 539-549 ◽  
Author(s):  
Camille Sandorfy

Recently Urban (Br. J. Anaesth. 2002, 89, 167) and Trudell (Br. J. Anaesth. 2002, 89, 32) assessed the present state of the art in anesthesiological research. This article is an attempt to add to the discussion some ideas from the chemist's point of view. General anesthesia is a matter of molecular associations. Among the intermolecular interactions that can be involved, weak hydrogen bonding and van der Waals forces are believed to be most important. A pluralistic view is proposed, thereby different anesthetics can choose different interactions in conformity with their chemical structure. This can involve proteins, lipids, and sugars. Special attention is given to glycoproteins and glycosphingolipids. A review with 90 references.


2003 ◽  
Vol 26 (4) ◽  
pp. 291-300 ◽  
Author(s):  
Carlo Riccardo Rossi ◽  
Simone Mocellin ◽  
Pierluigi Pilati ◽  
Mirto Foletto ◽  
Donato Nitti ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document